Previous 10 | Next 10 |
Recent PTAB ruling consolidated EDIT's power over the CRISPR patents but highlighted the binary nature of the dispute's outcomes: "Winner Takes All." Ticker to remain volatile until the results of CVC's appeal verdict. EDIT failed to differentiate itself from peers, choosing a mor...
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Comp...
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John...
ProQR press release (NASDAQ:PRQR): Q4 GAAP EPS of -€0.26. Revenue of €0.24M. “Following the disappointing readout of top-line results from the Illuminate trial of sepofarsen, we are conducting a comprehensive analysis of the data with the goal of providing ...
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome ...
For the second trading day in a row, investors sold off shares of ProQR Therapeutics (NASDAQ: PRQR) . The clinical-stage biotech's shares were hit by a series of analyst downgrades and price target cuts in the wake of the company's latest report about a once-promising drug candidate...
Citi has downgraded ProQR Therapeutics (PRQR -78.2%) to Neutral from Buy after the clinical-stage biotech company reported that its pivotal Phase 2/3 study for RNA therapy sepofarsen did not meet the main goal in Leber congenital amaurosis 10 (LCA10). After more than ~75% decline in valu...
Shares of ProQR Therapeutics (NASDAQ: PRQR) , a clinical-stage biopharmaceutical company, are sinking in response to lousy clinical trial results. The company's lead candidate, sepofarsen, failed to meet the primary endpoint in the Illuminate study. The stock was down 75.1% as of 12...
Gainers: Kaival Brands Innovations KAVL +42%. Y-mAbs Therapeutics YMAB +29%. China Online Education (NYSE:COE) +24%. Mr. Cooper COOP +20%. Zillow Z +19%. Carpenter Technology (NYSE:CRS) +19% Zillow ZG +18%. Eqonex EQOS +17%. Bloom Energy BE +17%. XPEL (...
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...